Vertex (VRTX) Moves Kidney Disease Drug to Phase 3 Development

Vertex (VRTX) Moves Kidney Disease Drug to Phase 3 Development

Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know

Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know

Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex moves kidney disease drug into late-stage testing

Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease

1 Top Growth Stock to Buy and Hold Forever

2 Rock-Solid Growth Stocks to Buy Right Now and Hold for at Least 5 Years

3 Unstoppable Stocks to Buy Hand Over Fist in April

Crispr Stock, A Cathie Wood Holding, Dives For The Fifth Straight Week — Here's Why

Brokers Suggest Investing in Vertex (VRTX): Read This Before Placing a Bet

Should You Invest in the iShares Biotechnology ETF (IBB)?

bluebird (BLUE) Misses on Q4 Revenues, Provides Portfolio Updates

Vertex Pharmaceuticals (VRTX) Rises As Market Takes a Dip: Key Facts

Vertex Pharmaceuticals (VRTX) Rises As Market Takes a Dip: Key Facts

Vertex (VRTX) Continues to Diversify Beyond CF Franchise

Vertex (VRTX) Continues to Diversify Beyond CF Franchise

Vertex (VRTX) Kidney Disease Drug to Enter Clinical Development

Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)